Eesti -
eesti -
Ravimiamet
gelofusine infusioonilahus
b. braun melsungen ag - želatiin - infusioonilahus - 4% 500ml 10tk
Eesti -
eesti -
Ravimiamet
primovist süstelahus süstlis
bayer ag - gadokseethape - süstelahus süstlis - 0,25mmol 1ml 5ml 10tk; 0,25mmol 1ml 7.5ml 5tk; 0,25mmol 1ml 10ml 10tk; 0,25mmol 1ml 10ml 5tk; 0,25mmol 1ml 7.5ml 1tk; 0,25mmol 1ml 5ml 5tk; 0,25mmol 1ml 10ml 1tk; 0,25mmol 1ml 7.5ml 10tk
Eesti -
eesti -
Ravimiamet
gelaspan infusioonilahus
b. braun melsungen ag - želatiin - infusioonilahus - 4% 500ml 10tk; 4% 500ml 20tk
Eesti -
eesti -
Ravimiamet
pemetrexed alvogen infusioonilahuse kontsentraadi pulber
alvogen ipco s.a.r.l. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 100mg 1tk
Eesti -
eesti -
Ravimiamet
pemetrexed alvogen infusioonilahuse kontsentraadi pulber
alvogen ipco s.a.r.l. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 1000mg 1tk
Eesti -
eesti -
Ravimiamet
pemetrexed zentiva infusioonilahuse kontsentraadi pulber
zentiva k.s. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastilised ained - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.